clinical trials

84 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.

Section: Internal MedicineJan 14, 2026

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression

clinical trials

Latest news

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

Omadacycline Establishes Noninferiority to Moxifloxacin in Community-Acquired Bacterial Pneumonia: The OPTIC-2 Phase 3b Trial Results

Blarcamesine in Early Alzheimer’s Disease: Promising Results Amidst Controversies

Structured Walking Protocol Boosts Post-Stroke Recovery: Insights from the Walk ‘n Watch Trial

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care

Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I

Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B

Stage-specific Tau-PET Dynamics in Biological Alzheimer’s Disease: Implications for Trial Design and Outcome Selection

NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS